How big is Heron Therapeutics, Inc.?

As of Jun 18, Heron Therapeutics, Inc. has a market capitalization of 297.50 million, with net sales of 148.51 million and a net profit of -7.79 million over the last four quarters. The company's shareholder's funds are -33.65 million, and total assets are 233.15 million.

Market Cap: As of Jun 18, Heron Therapeutics, Inc. has a market capitalization of 297.50 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Heron Therapeutics, Inc. reported net sales of 148.51 million and a net profit of -7.79 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to -33.65 million, while total assets were reported at 233.15 million.

What does Heron Therapeutics, Inc. do?

Heron Therapeutics, Inc. is a biotechnology company focused on developing pharmaceutical products for cancer and pain management. As of March 2025, it reported net sales of $39 million and a market cap of $297.5 million.

Overview:<BR>Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 39 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 297.50 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -4.45 <BR>Return on Equity: 27.36% <BR>Price to Book: -10.46<BR><BR>Contact Details:<BR>Address: 4242 Campus Point Ct Ste 200, SAN DIEGO CA: 92121 <BR>Tel: 1 858 2514400 <BR>Website: http://www.herontx.com/

Should I buy, sell or hold Heron Therapeutics, Inc.?

Who are in the management team of Heron Therapeutics, Inc.?

As of March 2022, the management team of Heron Therapeutics, Inc. includes Dr. Barry Quart as CEO and Chairman, and Ms. Kimberly Manhard as Executive VP of Drug Development. The Board of Directors features Mr. Craig Johnson as Lead Independent Director, along with Independent Directors Mr. Stephen Davis and Mr. Christian Waage.

As of March 2022, the management team of Heron Therapeutics, Inc. includes Dr. Barry Quart, who serves as the Chairman of the Board and Chief Executive Officer, and Ms. Kimberly Manhard, the Executive Vice President of Drug Development and a Director. Additionally, the Board of Directors features Mr. Craig Johnson as the Lead Independent Director, Mr. Stephen Davis as an Independent Director, and Mr. Christian Waage as an Independent Director.

Is Heron Therapeutics, Inc. overvalued or undervalued?

As of February 23, 2017, Heron Therapeutics, Inc. is considered risky and overvalued due to negative valuation ratios and underperformance compared to peers and the S&P 500.

As of 23 February 2017, the valuation grade for Heron Therapeutics, Inc. moved from does not qualify to risky, indicating a deterioration in its financial standing. The company appears to be overvalued given its negative valuation ratios, including a Price to Book Value of -11.26, an EV to EBIT of -124.99, and an EV to EBITDA of -365.76. <BR><BR>In comparison to its peers, Heron Therapeutics has a significantly worse EV to EBITDA ratio of -199.28, while Black Diamond Therapeutics, Inc., which is rated attractive, has a positive EV to EBITDA of 6.85. Additionally, Harpoon Therapeutics, Inc. shows a less negative EV to EBITDA of -13.41, highlighting the challenges faced by Heron in its industry. The stock has underperformed relative to the S&P 500, with a YTD return of -15.69% compared to the index's 12.22%, reinforcing the notion of overvaluation.

Is Heron Therapeutics, Inc. technically bullish or bearish?

As of August 25, 2025, Heron Therapeutics, Inc. is in a bearish trend with weak strength, indicated by bearish MACD, moving averages, and KST signals, while underperforming the S&P 500 with year-to-date and one-year returns of -15.69% and -33.85%, respectively.

As of 25 August 2025, the technical trend for Heron Therapeutics, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with a weak strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish signal from the KST on both weekly and monthly periods. Additionally, Bollinger Bands are indicating a bearish trend on the monthly timeframe. <BR><BR>In terms of performance, Heron has underperformed significantly against the S&P 500, with a year-to-date return of -15.69% compared to the S&P 500's 12.22%, and a one-year return of -33.85% versus the S&P 500's 17.14%.